Akebia Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 167
- Market Cap
- $319.6M
- Website
- http://www.akebia.com
- Introduction
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Cardiology: Most Read Stories From 2024
FDA approved Akebia Therapeutics’ vadadustat for anemia in CKD patients on dialysis. GLP-1RA and SGLT2i combination reduces CKD by 33%. Mediterranean and DASH diets lower CVD risk in T1D patients. Semaglutide shows benefits for CKD and CVD in T2D patients. GLP-1s improve CVD outcomes and weight loss in breast cancer patients.
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics CEO John Butler to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2024, discussing Vafseo® U.S. launch. Webcast available post-conference on Akebia's website.
Iron Deficiency Anemia Treatment Market To Achieve US$ 22.7 Billion By 2030, Expanding At 8.7% CAGR
The global iron deficiency anemia treatment market is projected to grow to US$ 22.7 billion by 2030, driven by increasing prevalence, awareness, and advancements in treatment options. Key players are focusing on product diversification, collaborations, and R&D to cater to the growing demand, especially in emerging markets.
Day 0 of Loss Streak for Akebia Therapeutics Stock with 0% Return (vs. 66% YTD) [12/1/2024]
Interactive model limits driver modifications per scenario; options: create new scenarios or reset existing modifications.
Mirum Pharmaceuticals' Volixibat Garners Buy Rating Amidst Breakthrough Therapy
Ed Arce of H.C. Wainwright maintains Buy rating on Mirum Pharmaceuticals (MIRM) with $66.00 price target, citing FDA's Breakthrough Therapy Designation for volixibat in treating cholestatic pruritus in PBC patients, and its potential to offer substantial improvement over existing therapies.
Akebia readies launch of anemia drug Vafseo; planning talks with FDA on pre-dialysis use
Akebia Therapeutics plans to launch its anemia drug Vafseo for dialysis patients in January 2025 and will discuss with the FDA about expanding its use to pre-dialysis patients.
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Akebia Therapeutics resubmitted its NDA to the FDA for vadadustat, an oral treatment for anemia in CKD patients on dialysis, including post-marketing safety data from Japan. The FDA's response is expected in 30 days, with a decision anticipated in six months. Vadadustat is approved in 35 countries.
© Copyright 2025. All Rights Reserved by MedPath